Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
|3||Active, not recruiting||
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
† Study has passed its completion date and status has not been verified in more than two years.